Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Delayed Quote USD

Imunon, Inc. (IMNN)

0.8766
+0.0046
+(0.53%)
At close: April 23 at 4:00:00 PM EDT
0.8899
-0.01
(-0.90%)
Pre-Market: 8:00:02 AM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael H. Tardugno Executive Chairman 346.74k -- 1951
Dr. Stacy R. Lindborg Ph.D. President, CEO & Director 532.12k -- 1971
Mr. David G. Gaiero CPA Chief Financial Officer 479.92k -- 1979
Dr. Khursheed Anwer M.B.A., Ph.D. Executive VP & Chief Scientific Officer 534.74k -- 1960
Mr. Timothy J. Tumminello CPA Chief Accounting Officer & Controller 108.31k -- 1958
Ms. Susan Mary Eylward General Counsel & Corporate Secretary -- -- 1980
Ms. Kristin Longobardi M.B.A. Senior Vice President of Strategic Operations -- -- --
Dr. Douglas V. Faller M.D., Ph.D. Chief Medical Officer -- -- 1953

Imunon, Inc.

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100 https://imunon.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
25

Description

Imunon, Inc., a clinical-stage biotechnology company, develops immunotherapies and next-generation vaccines. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Corporate Governance

Imunon, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC

Imunon, Inc. Earnings Date

Recent Events

April 4, 2025 at 12:00 AM UTC

S-1: Offering Registrations

March 24, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 19, 2025 at 12:00 AM UTC

DRS: Offering Registrations

February 27, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 27, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 24, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

September 20, 2024 at 12:00 AM UTC

S-1/A: Offering Registrations

Related Tickers

XLO Xilio Therapeutics, Inc.
0.7939
-1.99%
 
RNTX Rein Therapeutics Inc.
1.8600
+0.54%
 
IMNM Immunome, Inc.
8.50
+3.79%
 
IMTX Immatics N.V.
4.5100
+4.40%
 
CMMB Chemomab Therapeutics Ltd.
1.2000
+2.56%
 
CMPX Compass Therapeutics, Inc.
2.0700
+4.55%
 
CLDX Celldex Therapeutics, Inc.
19.43
+0.21%
 
ACHV Achieve Life Sciences, Inc.
2.4300
-2.02%
 
INZY Inozyme Pharma, Inc.
0.9806
-4.80%
 
HNSA.ST Hansa Biopharma AB (publ)
24.14
+8.25%